Top Stories
Enzyme replacement therapy BMN 401 missed one of the co-primary endpoints of the Phase III ENERGY 3 trial in children with ENPP1 deficiency.
The latest offerings follow strong debuts from Braveheart Bio and Attovia this week.
TransThera's Yochanra was conditionally approved for patients with FGFR2-mutated advanced cholangiocarcinoma previously treated with FGFR inhibitors.
The drugs will be delivered to eligible patients' homes for free, with same-day service available across more than 3100 US cities and towns.
The restructuring efforts are expected to result in $40 million in annualised savings.
Conference News
The 2026 World Conference on Lung Cancer (WCLC) will take place in Seoul, South Korea, from September 12 to 15, 2026. At this year’s meeting, Henlius will present multiple new findings from its innova...
HONG KONG, August 7, 2026 - (ACN Newswire) - On August 3, 2026, Shaanxi Micot Pharmaceutical Technology Co., Ltd. ("Micot Pharma"; 2335.HK) announced positive topline data from the Phase II clinical t...
First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor supportAnalysis of blood and ...
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expecte...
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive meta...
